A British baby’s death this year after getting Novartis’s gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment’s risks.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
For two men trained as scientists, the bosses of Britain’s major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.
Julien is a dynamic business developer with a proven track record in selling to world-class pharmaceutical companies and some of the most promising biotech and health start-ups, a « hunter » focused on providing tailored services and solutions in clinical operations, data management, biostatistics and patient recruitment. Specialized in real-world evidence generation: epidemiological studies, non-interventional studies, post-marketing requirements but also pricing and market access strategies for biotech and medtech companies.